• 1.

    Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2:292298.

    • Search Google Scholar
    • Export Citation
  • 2.

    Besarab A, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339:584590.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Drüeke TB, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355:20712084.

  • 4.

    Singh AK, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:20852098.

  • 5.

    Pfeffer MA, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361:20192032.

  • 6.

    Macdougall IC, et al. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 2019; 380:447458.

  • 7.

    Macdougall IC, et al. Iron management in chronic kidney disease: Conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) controversies conference. Kidney Int 2016; 89:2839.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Gupta N, Wish JB. Hypoxia-inducible factor prolyl hydroxylase inhibitors: A potential new treatment for anemia in patients with CKD. Am J Kidney Dis 2017; 69:815826.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Locatelli F, et al. Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients. Am J Nephrol 2017; 45:187199.

KDIGO Quo Vadis: Anemia

  • 1 Iain C. Macdougall, MD is Consultant Nephrologist and Professor of Clinical Nephrology, Department of Renal Medicine at King’s College Hospital, London, United Kingdom.
Restricted access
Save